Supply Chain / Indian Pharma Manufacturing: Back in Business
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
india
The COVID-19 Vaccine Rush / Nationalism, Access & IP Issues
The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer nations. While some are calling for…
India / 200% Pharma Sector Budget Boost; 3x Industry Growth in Next Decade; Pfizer Vaccine Rebuffed
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
India / Six Companies at the Forefront of COVID-19 Vaccine Development
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with…
In Conversation
Interview: VS Reddy – Founder and Managing Director, British Biologicals, India
VS Reddy, fondly known as ‘The Protein Man of India’ and founder and managing director of British Biologicals, India’s leading nutraceutical company, provides insights into the pioneering role played by British Biologicals in raising awareness about and fostering the use of nutraceuticals in India, while he documents his plans to leverage the company’s unique brands to swiftly strengthen its international…
Indian Generics Companies in the US Snapshot
The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made…
Related Report
Digital Health: India
An insight into biosimilars & biologics in Indian Pharma. Prepared in association with Nishith Desai &…
Coronavirus / Indian Pharma Supply Chain Hit by Covid-19 Outbreak
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions…
Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven…
India: Good Endings, Good Beginnings
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take…
Africa: The Launchpad for Indian Pharma
Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming…
Geopolitics / Three More Key Issues for Pharma: Regulatory Assertiveness, Climate Change & India’s Health Policy Renaissance
Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be…
Supply Chain / Indian Pharma Manufacturing: Back in Business
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
Meeting US FDA Standards Across the Board in India
In a context where even well-established, multi-billion-dollar domestic companies have received warning letters…
Mexico / Indian Investment to Bolster Domestic Supply Chain post-COVID
COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in…
News Roundup / Indian Pharma: January 2020
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the…
US Generics / Biocon’s Recipe for Success in a Competitive Market
Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of…
Indian Pharma Manufacturing: Serving the World
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign…
10 Pharma Leaders to Know in India
Indian pharma companies provide affordable generic drugs to patients in almost all countries across the globe,…
India: Still a Land of Opportunity for MNCs
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India…
China: Indian Pharma Firms Incoming
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports…
India: Creating An Innovative Healthcare Ecosystem
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based…
India’s Drug Regulatory Reforms: Building Trust
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more…
India / 200% Pharma Sector Budget Boost; 3x Industry Growth in Next Decade; Pfizer Vaccine Rebuffed
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
Quality Compliance in Indian Pharma: The Learning Curve
One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance.…
India / Biocon's New Facility & Expansion in APAC
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with…
LatAm / What Can Brazil’s Pharma Industry Learn from India?
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to…
Indian Generics in the USA / Destined for More Success?
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…
MNCs’ Healthcare Access Initiatives in India
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to…
India: An Emerging Knowledge Superpower
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we…
India Healthcare: “Modicare” Lives On
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s…
Gender Diversity in Indian Pharma
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…
LatAm / Big Indian Investment; Argentina's COVID-19 Woes; Cannabis ‘Green Rush’ in Mexico
The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma…